Equipment in Residence: An FDA/NIIMBL Collaboration

This Request for Information (RFI) invites interested parties to submit information for consideration in the “Equipment in Residence Program: An FDA/NIIMBL Collaboration” (abbreviated EiRP).

NIIMBL and the U.S. Food and Drug Administration (FDA) are collaborating on a program whereby new and emerging manufacturing-related and analytical measurement technologies can be made temporarily available to FDA staff for research and demonstration purposes. Technologies selected for EiRP will reside in an FDA lab for a period of at least three months and typically no more than twelve months.

The purpose of EiRP is to establish a test bed for evaluation of new technologies used in medical product manufacturing to increase efficiency of evaluation and adoption of new technologies. This will provide FDA staff with exposure to novel technologies and equipment in a pre-competitive space (not related to a specific product submission or a directly regulated product) to gain a better understanding of technologies in alignment with FDA priorities. Additionally, a select group of FDA researchers will use the technologies to address regulatory science gaps with the aim of publishing technical manuscripts of their findings.

As part of this effort, NIIMBL receives from the FDA a list of general technology areas of interest. NIIMBL issues a Request for Information from relevant organizations within the biopharmaceutical manufacturing ecosystem with new or emerging technologies that address those general technology areas of interest. Organizations with technologies or equipment of interest may then be invited to share more information through a Request for Application.

Selected organizations will have their equipment / technology placed in residence at an FDA laboratory for a limited period of time.

Questions can be sent to [email protected].

Submission Deadline: July 21, 2026, at 5 pm ET.